GET THE APP

A retrospective analysis of frequency of ALK gene rearrangement in Saudi lung patients
..

Cancer Science & Therapy

ISSN: 1948-5956

Open Access

A retrospective analysis of frequency of ALK gene rearrangement in Saudi lung patients


7th Global Summit on Cancer Therapy

October 05-07, 2015 Dubai, UAE

Fouad Hassan Al-Dayel, Hamad Al Husaini, Shamayel Mohammed, Asma Tulbah and Khawla Al Kuraya

King Faisal Specialist Hospital and Research Centre, Saudi Arabia

Scientific Tracks Abstracts: J Cancer Sci Ther

Abstract :

Background: Lung carcinoma represents 2.6% of cancer seen at King Faisal Specialist Hospital and Research Centre (KFSH & RC) and 4.5% of cancers in Saudi Arabia as per Saudi Cancer Registry. EML4-ALK re-arrangements are found to play an oncogenic driver role in lung adenocarcinoma tumor genesis in 3-6% of cases. ALK gene rearrangement testing can identify patients with adenocarcinoma who are sensitive to ALK kinase inhibitors. However, no data are available on the prevalence of ALK rearrangements changes in Middle Eastern population. Therefore, we carried out this study to evaluate the prevalence of ALK gene rearrangements in lung adenocarcinoma of Saudi patients. Methods: ALK gene rearrangements were studied using fluorescence in situ hybridization (FISH) on 198 adeno-carcinoma samples utilizing tissue microarray format. ALK gene rearrangements tested using break-apart probes from Vysis. Results: One hundred ninety eight (198) lung adenocarcinoma cases were evaluated. Eleven (11) cases exhibited ALK gene rearrangement (5.5%). Seven (7) of these cases were metastatic lung adenocarcinoma (stage IV). Mean age of the patient is 51 years (21-79 years). History of smoking was available on only four (4) cases (2 smokers and 2 non-smokers). All cases were moderately to poorly differentiated adenocarcinoma. None of our cases showed signet cells or abundant intracellular mucin. Conclusion: The findings of this retrospective study show that the incidence of ALK gene rearrangements positive adenocarcinoma in Saudi patients is 5.5%. This is similar to the published data.

Biography :

Fouad Hassan Al-Dayel is currently working as Chairman of Department of Pathology and Laboratory Medicine, King Faisal Specialist Hospital and Research Centre, Saudi Arabia. He is also a Professor of Pathology, College of Medicine, Al Faisal University, Saudi Arabia. His most of the research interest is Lung Pathology, Bone Pathology, Diagnostic Molecular Oncology of solid tumors, Stem Cell Applications in Clinical and Research (Cell Therapy). He has 128 publications in many reputed international journals.

Email: dayelf@kfshrc.edu.sa

Google Scholar citation report
Citations: 3968

Cancer Science & Therapy received 3968 citations as per Google Scholar report

Cancer Science & Therapy peer review process verified at publons

Indexed In

 
arrow_upward arrow_upward